Nucl Med Mol Imaging.
2012 Jun;46(2):129-133.
Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease
- Affiliations
-
- 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
- 2Department of Nuclear Medicine and Center for PET/CT, Zentralklinik Bad Berka, 99437 Bad Berka, Germany. richard.baum@zentralklinik.de
Abstract
- Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome with a variety of benign and malignant tumors such as retinal and central nervous system hemangioblastomas, endolymphatic sac tumors, renal cysts and tumors, pancreatic cysts and tumors, pheochromocytomas, and epididymal cystadenomas. Cross-sectional modalities (computed tomography and magnetic resonance imaging) as well as ultrasound play a major role in the initial evaluation and follow-up of the various manifestations of VHL disease. Ga-68-labeled somatostatin receptor analogs already have a significant role in the diagnosis, staging, and therapy management of neuroendocrine neoplasms and neural crest tumors. Herein, we report a case presenting a variety of malignancies in VHL and showing the usefulness of Ga-68 somatostatin receptor PET/CT as a one-stop-shop imaging modality in the management of VHL disease.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- 68Ga‑DOTATOC Embolus Manifestation and Spontaneous Resolution by PET/CT
- 68Ga‑DOTANOC PET/CT for Screening and Surveillance of Von Hippel‑Lindau (VHL) disease
- Brain Metastasis of Renal Cell Carcinoma in Von Hippel-Lindau Disease
- Papillary Cystadenoma of the Epididymis: Component of von Hippel-Lindau Syndrome: A case report
- Von Hippel-Lindau Syndrome: Demonstration of Entire Disease Spectrum with 68Ga-DOTANOC PET-CT
